Isoniazid News and Research

RSS

TB preventive treatment delivers real-world gains for people with HIV

Tuberculosis (TB) is responsible for about a quarter of all AIDS deaths. In 2024, it was also the leading cause of death among people with HIV. This is despite TB being a preventable and curable disease.

17 Aug 2026

Can ibuprofen improve drug-resistant tuberculosis treatment?

While ibuprofen reduced inflammatory markers in drug-resistant TB patients, it did not enhance treatment outcomes, indicating the need for further research.

3 Jul 2026

High adherence and safety found in short TB treatments

A study comparing one- and three-month antibiotic treatments to prevent active tuberculosis (TB) finds that a high percentage of patients successfully completed both regimens and suffered few adverse side effects.

10 Feb 2026

High-dose rifampicin does not improve survival in tuberculosis meningitis

Each year, 11 million people worldwide develop tuberculosis, and about 1.4 million die from it. Meningitis occurs in 1–2% of patients and is the most severe complication of tuberculosis, arising when the bacteria reach the brain.

17 Dec 2025

New clinical trial shows promise for shorter TB treatment

New clinical trial results presented by TB Alliance at the Union World Conference on Lung Health show that the novel antibiotic candidate sorfequiline (TBAJ-876), a next-generation diarylquinoline, has the potential to improve tuberculosis (TB) treatment when combined with pretomanid and linezolid in a treatment regimen known as "SPaL."

19 Nov 2025

Experimental cancer drug shows promise in boosting tuberculosis treatment

An experimental drug now in clinical trials as a cancer treatment could help boost the power of first-line tuberculosis (TB) treatments by helping infected cells die a gentler death, Johns Hopkins Medicine investigators report, based on mouse-model research of the lung-damaging disease.

21 Apr 2025

Multidrug-resistant TB in children is rising: Urgent global action needed

Researchers analyzed global trends in multidrug-resistant tuberculosis (MDR-TB) among children and adolescents, revealing rising incidence rates, gender disparities, and the disproportionate impact on low-income regions.

12 Feb 2025

Unraveling the mystery of drug-induced liver injury

DILI is broadly categorized into intrinsic and idiosyncratic types. Intrinsic hepatotoxins, such as APAP, cause dose-dependent injury, while idiosyncratic DILI involves complex immune and metabolic interactions that remain poorly understood.

13 Dec 2024

Quabodepistat combo shows promise for safer, faster tuberculosis treatment

Study highlights the safety and early bactericidal activity of quabodepistat when combined with delamanid, bedaquiline, or both, offering potential for shorter and more tolerable tuberculosis treatment regimens.

1 Dec 2024

Study finds weakness in drug-resistant tuberculosis pathogens

A University of Otago-led study has found highly vulnerable weakness in drug-resistant Mycobacterium tuberculosis, offering a new way to kill them.

13 Nov 2024

Rutgers study sheds light on how bedaquiline fights drug-resistant tuberculosis

Rutgers Health research has uncovered why a relatively new antibiotic for tuberculosis (TB) works against multidrug-resistant strains, potentially inspiring improved treatments and drug development strategies.

13 Nov 2024

Innovative fingerprint technique detects TB antibiotics with high accuracy

A fingerprint may soon be all a doctor needs to check whether tuberculosis patients are taking their antibiotics – thanks to a new study led by the University of Surrey.

24 Jun 2024

Second-line treatment for drug-resistant tuberculosis is as effective as first-line medicines

Patients who have drug-resistant tuberculosis (TB) have a similar microbiological response to bedaquiline-based second-line medications as patients with drug-sensitive TB taking first-line regimens, according to researchers at Weill Cornell Medicine in New York and GHESKIO Centers in Haiti.

27 Feb 2024

New study reveals turmeric and Tinospora Cordifolia reduce liver injury risk in TB patients

The effectiveness of herbs and alternative medicines in preventing liver injury induced by anti-tuberculosis (anti-TB) drugs.

16 Nov 2023

New TB treatments tackle the disease without wrecking your microbiome

Researchers in a study published in The Lancet Microbe examined how various tuberculosis treatment regimens affect the respiratory microbiome. They found that certain treatments control tuberculosis effectively while minimally impacting the diversity and health of the respiratory microbiome.

15 Oct 2023